Sirolimus nephrotoxicity: experimental and clinical data;Néphrotoxicité du sirolimus : données cliniques et expérimentales

Nephrologie et Therapeutique

Volumn 2, Issue 4, 2006, Pages 183-190

  Pallet, Nicolas ^a,b   Thervet, Eric ^a,b   Legendre, Christophe ^a   Anglicheau, Dany ^a,b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b INSERM   (France)

Author keywords

mTOR; Nephrotoxicity; Sirolimus

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; RAPAMYCIN; VASCULOTROPIN;

ARTICLE; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; NEPHROTOXICITY; PROTEINURIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

CELL PROLIFERATION; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MODELS, ANIMAL; PROTEIN KINASES; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 33748451305     PISSN: 17697255     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nephro.2006.04.006     Document Type: Article

References (65)

1. Thomas G., and Hall M.N. TOR signalling and control of cell growth. Curr. Opin. Cell Biol. 9 (1997) 782-787
2. s6k. EMBO J. 16 (1997) 3693-3704
3. Burnett P.E., Barrow R.K., Cohen N., Snyder S.H., and Dabatini D.M.R.A.F.T. 1-phosphorylation of the translational regulators stability p70 S6 kinase and 4E-BP1. Proc. Natl. Acad. Sci. USA 95 (1998) 1432-1437
4. Kahan BD for the rapamune US study group. Efficacy of sirolimus compared with azathioprine for the reduction of acute renal allograft rejection: a randomised multicentre study. Lancet 356 (2000) 194-202
5. Keogh A., Richardson M., Ruygrok P., Spratt P., Galbraith A., O'Driscoll G., et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at two years: a randomized clinical trial. Circulation 110 (2004) 2694-2700
6. Snell G.I., Valentine V.G., Vitulo P., Glanville A.R., McGiffin D.C., Loyd J.E., et al. RAD-B159 study group. Everolimus versus azathioprine in maintenance lung transplant recipients: an International, randomized, double-blind clinical trial. Am. J. Transplant. 6 (2006) 169-177
7. Serruys P.W., de Jaegere P., Kiemeneij F., Macaya C., Rutsch W., Heyndrickx G., et al. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent study group. N. Engl. J. Med. 331 (1994) 489-495
8. Morice M.C., Serruys P.W., Sousa J.E., Fajadet J., Ban Hayashi E., Perin M., et al. Ravel study group. Randomized study with the sirolimus-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. 346 (2002) 1773-1780
9. Sawyers M.L. Will mTOR maker it cancer drugs?. Cancer Cell (2003) 343-348
10. Bjornsti M.A., and Houghton P.J. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer 4 (2004) 335-348
11. Beuvink I., Boulay A., Fumagalli S., Zilbermann F., Ruetz S., O'Reilly T., et al. The mTOR inhibitor RAD-001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120 (2005) 747-759
12. Yu K., Toral-Barza L., Discafani C., Zhang W.G., Skotnicki J., Frost P., et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocrine-Relat Cancer 8 (2001) 249-258
13. Mita M.M., Mita A., and Rowinsky E.K. The molecular target of Rapamycin (mTor) as a therapeutic target against cancer. Cancer Biol. Ther. 2 Suppl 1 (2003) S169-S177
14. Poh T.W., and Pervaiz S. LY294002 and LY303511 sentitize tumor cells to drug-induced apoptosis via intracellular hydrogen peroxide production independent of the phosphoinositide 3-kinase-Akt pathway. Cancer Res. 65 (2005) 6264-6274
15. Inoki K., Corradetti M.N., and Guan K.L. Dysregulation of the TSC mTOR pathway in human disease. Nat. Gen. 37 (2005) 19-24
16. Tao Y., Kim J., Schrier R.W., and Edelstein C.L. SRL markedly slows disease progression in a rat model of polycystic kidney disease. J. Am. Soc. Nephrol. 16 (2005) 46-51
17. MacDonald A.S. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus-cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 71 (2001) 271-280
18. Meier-Kriesche H.U., Steffen B.J., and Chu A.H. Sirolimus with neoral versus mycophenolate mofetil with neoral is associated with decreased renal allograft survival. Am J Tranplant. 4 (2004) 2058-2066
19. Eisen H.J., Tuzcu E.M., Dorent R., et al. RAD-B253 study group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N. Engl. J. Med. 349 (2003) 847-858
20. Mendez R., Gonwa T., Yang H.C., Weinstein S., Jensik S., Steinberg S., and Prograf study group. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at one year. Transplantation 80 (2005) 303-309
21. Hamdy A.F., El-Agroudy A.E., Bakr M.A., Mostafa A., El-Baz M., El-Shahawy E.-M., et al. Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation. Am. J. Transplant. 10 (2005) 2531-2538
22. Meier-Kriesche H.U., Schold J.D., Srinivas T.R., Howard R.J., Fujita S., and Kaplan B. Sirolimus in combination with tacrolimus is associated with worse allograft survival compared to mycophenolate mofetil combined with tacrolimus. Am. J. Transplant. 9 (2005) 2273-2280
23. Nielsen F.T., Ottosen P., Starklint H., and Dieperink H. Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat. Nephrol. Dial. Transplant. 18 (2003) 491-496
24. Andoh T.F., Lindsley J., Franceschini N., and Benett W.M. Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation 62 (1996) 311-316
25. Napoli K.L., Wang M.E., Strepkowski S.M., and Kahan B.D. Relative tissue distribution of cyclosporine and sirolimus after concomitant peroral administration to the rat: evidence for pharmakinetic interactions. Ther. Drug Monit. 20 (1998) 123-133
26. Podder H., Stepkowski S.M., Napoli K.L., Clark J., Verani R.R., Chou T.C., et al. Pharmacokinetic interactions augment toxicities of sirolimus-cyclosporine combination. J. Am. Soc. Nephrol. 12 (2001) 1059-1071
27. o 144)
28. Shihab F.S., Andoh T.F., Tanner A.M., Noble N.A., Border W.A., Franceschini N., et al. Role of transforming growth factor β-1 in experimental chronic nephropathy. Kidney Int. 49 (1996) 1141-1151
29. Shihab F.S., Yi H., Bennett W.M., and Andoh T.F. Effect of nitric oxide modulation on TGF-beta1 and matrix proteins in chronic cyclosporine nephrotoxicity. Kidney Int. 58 3 (2000) 1174-1185
30. Shihab F.S., Bennet W.M., Tanner A.M., and Andoh T.F. Angiotensin II blockade decreases TGF-β1 and matrix proteins in chronic cyclosporine nephropathy. Kidney Int. 52 (1997) 660-673
31. Shihab F., Bennet W.M., Yi H., Choi S.O., and Andoh T.F. Sirolimus increases transforming growth factor-β1 expression and potentiates chronic cyclosporine nephrotoxicity. Kidney Int. 65 (2004) 1262-1271
32. McTaggart R.A., Gottlieb D., Brooks J., Bacchetti P., Roberts J.P., Tomlanovich S., and Feng S. Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am. J. Transplant. 3 (2003) 416-423
33. Stallone G., Infante B., Schena A., Battaglia M., Ditonno P., Loverre A., et al. Addition of Sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1-year graft. J. Am. Soc. Nephrol. 15 (2004) 228-233
34. Smith K.D., Wrenshall L.E., Nicosia R.F., Pichler R., Marsh C.L., Alpers C.E., et al. Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use. J. Am. Soc. Nephrol. 14 (2003) 1037-1045
35. Boratynska M., Banasik M., Patrzalek D., Szyber P., and Klinger M. Sirolimus delays recovery from post transplant renal failure in kidney graft recipients. Transplant. Proc. 37 (2005) 839-842
36. Simon J.F., Swanson S.J., Agodoa L.Y., Cruess D.F., Bohen E.M., and Abbott K.C. Induction sirolimus and delayed graft function after deceased donor kidney transplantation in the United States. Am. J. Nephrol. 24 (2004) 393-399
37. Lieberthal W., Fuhro R., Andry C.C., Rennke H., Abernathy V.E., Koh J.S., et al. Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am. J. Physiol. Renal Physiol. 281 (2001) F693-F706
38. Fuller T.F., Freise C.E., Serkova N., Niemann C.U., Olson J.L., and Feng S. Sirolimus delays recovery of rat kidney transplants after ischemia-reperfusion injury. Transplantation 76 (2003) 1594-1599
39. Pallet N., Thervet E., Le Corre D., Knebelmann B., Nusbaum P., Tomkiewicz C., et al. Rapamycin inhibits human epithelial cells proliferation: effect on cyclin D3 mRNA expression and stability. Kidney Int. 67 (2005) 2422-2433
40. Diekmann F., Waiser J., Fritsche L., Dragun D., Neumayer H.H., and Budde K. Conversion to rapamycin in renal allograft recipients with biopsy-proven calcineurin inhibitor-induced nephrotoxicity. Transplant. Proc. 33 (2001) 3234-3235
41. Bumbea V., Kamar N., Ribes D., Esposito L., Modesto A., Guitard J., et al. Long-term results in renal transplant patients with allograft dysfonction after switching from calcineurin inhibitors to sirolimus. Nephrol. Dial. Transplant. 20 11 (2005) 2517-2523
42. Letavernier E., Pe'raldi M.N., Pariente A., Morelon E., and Legendre C. Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 80 (2005) 1198-1203
43. Dervaux T., Caillard S., Meyer C., Ellero B., Woehl-Jaegle M.L., Hannedouche T., et al. Is sirolimus responsible for proteinuria?. Transplant. Proc. 37 (2005) 2828-2829
44. Morelon E., and Kreis H. Sirolimus therapy without calcineurine inhibitors: Necker hospital 8-years experience. Transplant. Proc. 35 (2003) 52S-57S
45. Lorber M.I., Mulgaonkar S., Butt K.M., Elkhammas E., Mendez R., Rajagopalan P.R., et al. B251 study group. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant patients: a three years randomized, multicenter, phase III study. Transplantation 80 (2005) 244-252
46. Senior P.A., Paty B.W., Cockfield S.M., Ryan E.A., and Shapiro A.M. Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. Am. J. Transplant. 9 (2005) 2318-2323
47. Butani L. Investigation of pediatric renal transplant recipients with heavy proteinuria after sirolimus rescue. Transplantation 78 9 (2004) 1362-1366
48. Ibanez J.P., Monteverde M.L., and Goldberg J. Sirolimus in pediatric renal transplantation. Transplant. Proc. 37 (2005) 682-686
49. Aurina S., Campistol J.M., Piera C., Diekmann F., Campos B., Campos N., et al. Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfonction: changes in glomerular haemodynamics and proteinuria. Nephrol. Dial. Transplant. 21 (2006) 488-493
50. Izzedine H., Brocheriou I., and Frances C. Post-transplant proteinuria and sirolimus. N. Engl. J. Med. 359 (2005) 2088-2089
51. Straathof-Galema L., Wetzels J.F., Dijkman H.B., Steenbergen E.J., and Hilbrands L.B. Sirolimus-associated heavy proteinuria in a renal transplant recipient : evidence for a tubular mechanism. Am. J. Transplant. 6 (2006) 429-433
52. Daniel C., Ziswiler R., Frey B., Pfister M., and Marti H.P. Proinflamatory effects in experimental mesangial proliferative glomerulonephritis of the immunosuppressive agent SDZ RAD, a rapamycin derivate. Exp. Nephrol. 8 (2000) 52-62
53. Fervenza F.C., Fitzpatrick P.M., Mertz J., Erickson S.B., Liggett S., Popham S., et al. Mayo nephrology collaborative committee. Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulonephrtis. Nephrol Dial Transpl 19 (2004) 1288-1292
54. Bonegio R.G., Fuhro R., Wang Z., Valeri C.R., Andry C., Salant D.J., et al. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflamation and fibrosis in experimental membranous nephropathy. J. Am. Soc. Nephrol. 16 (2005) 2063-2072
55. Ninova D., Covarrubias M., Rea D.J., Park W.D., Grande J.P., and Stegall M.D. Acute nephrotoxicity of tacrolimus and sirolimus in renal isografts: differential intragraft expression of transforming growth factor-beta1 and alpha-smooth muscle actin. Transplantation 78 (2004) 338-344
56. Reynolds J.C., Agodoa L.Y., Yuan C.M., and Abbott K.C. Thrombotic microangiopathy after renal transplantation in the United States. Am. J. Kidney Dis. 42 (2003) 1058-1068
57. Fortin M.C., Raymond M.A., Madore F., Fugere J.A., Paquet M., St-Louis G., et al. Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination. Am. J. Transplant. 4 (2004) 946-952
58. Langer R.M., Van Buren C.T., Katz S.M., and Kahan B.D. De novo hemolytic uremic syndrome after kidney transplantation in patients treated with cyclosporine-sirolimus combination. Transplantation 73 (2002) 756-760
59. Robson M., Cote I., Abbs I., Koffman G., and Goldsmith D. Thrombotic microangiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage?. Am. J. Transplant. 3 (2003) 324-327
60. Saikali J.A., Truong L.D., and Suki W.N. Sirolimus may promote thrombotic microangiopathy. Am. J. Transplant. 3 (2003) 229-230
61. Guba M., von Breitenbuch P., Steinbauer M., Koehl G., Flegel S., Hornung M., Bruns, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 8 (2002) 128-135
62. Bruns C.J., Koehl G.E., Guba M., Yezhelyev M., Steinbauer M., Seeliger H., et al. Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer. Clin. Cancer Res. 10 (2004) 2109-2119
63. Babinska A., Markell M.S., Salifu M.O., Akoad M., Ehrlich Y.H., and Kornecki E. Enhancement of human platelet aggregation and secretion induced by rapamycin. Nephrol. Dial. Transplant. 13 (1998) 3153-3159
64. Sartelet H., Toupance O., Lorenzato M., Fadel F., Noel L.H., Lagonotte E., et al. Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidney. Am. J. Transplant. 5 (2005) 2441-2447
65. Pelle G., Xu Y., Khoury N., Mougenot B., and Rondeau E. Thrombotic microangiopathy in marginal kidneys after sirolimus use. Am. J. Kidney Dis. 46 (2005) 1124-1128